NAII Natural Alternatives International Inc.

CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism

CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism

CARLSBAD, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands will exhibit at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy on September 7-10, 2024. ESPEN 2024 offers a unique platform for companies to present and educate on innovative science in clinical nutrition and metabolism, fostering collaboration with physicians, dietitians, pharmacists, nutritionists, scientists, and nurses.

The NAI and CarnoSyn® Brands team will be available at stand #16 to discuss the latest clinical evidence of TriBsyn™, a patent-pending formula that utilizes proprietary technology to increase beta-alanine bioavailability and absorption, while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine. TriBsyn™ provides new opportunity to reach untapped consumers from older adults to vegans and anyone focused on wellness. Congress attendees are invited to visit the stand to learn more about this new product innovation.

Aaron Starr, Vice President, CarnoSyn® Brands stated, “We are excited to exhibit TriBsyn™ at this year’s ESPEN Congress on Clinical Nutrition and Metabolism and to share details behind the clinically proven formula. There is an evolving need and growing demand for healthy aging and wellness solutions, and this proprietary carnosine booster is a game changer for dietary supplement categories, as well as for fortified and medical foods, seeking benefit focus on muscle vitality, cognitive performance, and anti-aging support.”

Following ESPEN, the team will attend the 20th European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain on September 18-20.

Find out more about TriBsyn™ by visiting ESPEN stand #16 or .

About CarnoSyn® Brands:

CarnoSyn® Brands feature three clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder allows NAI to broaden their product offerings within the dietary supplement category, including medical and other fortified food products. To learn more about SR CarnoSyn® in active nutrition and wellness, visit . For more information about the latest innovation, TriBsyn™, visit .

About NAI:

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit .

Contact:

Renee Michaelson

Director of Global Marketing

NAI/CarnoSyn® Brands

(760) 736-7700



EN
26/08/2024

Underlying

Reports on Natural Alternatives International Inc.

 PRESS RELEASE

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Res...

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $28.8 million for the third quarter of fiscal year 2025 compared to a net loss of $1.6 million, or $0.27 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, 2025, ...

 PRESS RELEASE

Natural Alternatives International and CarnoSyn® Brands Publish Clinic...

Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination CARLSBAD, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands today announced the publication of positive clinical trial results in the journal showing that TriBsyn™ supplementation led to significantly greater bioavailability and efficiency of beta-alanine along with the elimination of paresthesia, a common beta-alanine side effect. ...

 PRESS RELEASE

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Res...

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results CARLSBAD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $34.1 million for the second quarter of fiscal year 2025 compared to a net loss of $3.1 million, or $0.52 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months ended December ...

 PRESS RELEASE

Natural Alternatives International, Inc. Announces 2025 Q1 Results

Natural Alternatives International, Inc. Announces 2025 Q1 Results CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.0 million, or $0.33 per diluted share, on net sales of $33.2 million for the first quarter of fiscal year 2025 compared to a net loss of $0.7 million, or $0.12 per diluted share, in the first quarter of the prior fiscal year. Net sales during the three months ended September 30, 2024, d...

 PRESS RELEASE

CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Cli...

CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism CARLSBAD, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands will exhibit at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy on September 7-10, 2024. ESPEN 2024 offers a unique platform for companies to present and educate on innovative science in clinical nutrition and metabolism, fostering collaboration with physicians, dietitians, pharmacists, nutritionists, scientists, and nurses. The NAI and CarnoSyn®...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch